aTyr Pharma Reports $10.8 Million Net Loss in Q1 2026, Terminates Collaboration with Kyorin

aTyr Pharma, Inc. reported its financial results for the first quarter of 2026, revealing a consolidated net loss of $10.8 million, a decrease from a net loss of $14.9 million in the same period of 2025. The company’s operating expenses totaled $11.4 million, down from $15.8 million year-over-year, primarily due to reduced research and development costs associated with the completion of the EFZO-FIT study for its lead candidate, efzofitimod. The net loss per share improved to $(0.11) from $(0.17) in the prior year, reflecting a smaller loss despite an increase in the number of shares outstanding.

Total assets as of March 31, 2026, were reported at $79.7 million, a decline from $93.0 million at the end of 2025. This decrease was attributed to a reduction in cash and cash equivalents, which fell to $10.0 million from $10.7 million, and a decrease in available-for-sale investments, which dropped to $56.5 million from $67.9 million. The company’s accumulated deficit increased to $617.0 million, highlighting ongoing financial challenges as it continues to invest in clinical development without generating revenue from product sales.

In terms of strategic developments, aTyr Pharma announced the termination of its collaboration agreement with Kyorin Pharmaceutical Co., Ltd. on May 12, 2026. This agreement had granted Kyorin exclusive rights to develop and commercialize efzofitimod in Japan. The termination will take effect 90 days after the notice, resulting in the loss of potential milestone payments totaling $155 million and royalties on net sales in Japan. Following this termination, aTyr will regain global rights to efzofitimod, which is currently in clinical development for interstitial lung disease.

Operationally, the company reported a decrease in research and development expenses to $7.3 million from $11.8 million, primarily due to the completion of the EFZO-FIT study. General and administrative expenses increased slightly to $4.1 million from $4.0 million, driven by higher stock-based compensation. The company continues to focus on its clinical pipeline, with plans for a Phase 3 study of efzofitimod in pulmonary sarcoidosis, which will require significant additional funding.

Looking ahead, aTyr Pharma anticipates that its existing cash and investments will be sufficient to meet its operational needs for at least the next year. However, the company acknowledges the necessity of raising additional capital through equity offerings or partnerships to support ongoing clinical trials and development efforts. The future of its product candidates, including efzofitimod, remains contingent on successful clinical outcomes and regulatory approvals, which are critical for potential commercialization.